New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
09:39 EDTGSK, PBYIASCO data shows 'challenges' to Puma's neratinib
Citigroup believes data presented over the weekend at ASCO showed 'some challenges' to Puma Biotechnology's (PBYI) neratinib. Citi says the failed ALLTO trail announced by GlaxoSmithKline (GSK) shows how difficult it is to show a benefit in the adjuvant setting. Citi added that its cautious on the outcome for neratinib is the adjuvant ExteNET setting. Shares of Puma are down 17% to $63.70 in early trading. Citi keeps a Buy rating on the stock with a $123 price target.
News For PBYI;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 5, 2015
15:02 EDTGSKNotable companies reporting before tomorrow's open
Subscribe for More Information
10:04 EDTPBYIOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:31 EDTGSKGlaxoSmithKline, partners make EU submission for gene therapy to treat ADA-SCID
Subscribe for More Information
07:47 EDTPBYIPuma Biotechnology downgraded to Market Perform from Outperform at Cowen
Cowen downgraded Puma Biotechnology to Market Perform from Outperform citing a lack of any major catalysts and substantial valuation.
May 3, 2015
18:11 EDTGSKSiemens investigated by Chinese regulator last year, Reuters says
Subscribe for More Information
May 1, 2015
07:43 EDTGSKExpensive drugs drove over 25% of 2013 Medicare drug spending, WSJ says
Subscribe for More Information
April 30, 2015
16:59 EDTGSKGlaxoSmithKline, Theravance announce FDA approval of Breo Ellipta
Subscribe for More Information
15:20 EDTGSKGlaxo says FDA issued CRL on use of Breo Ellipta in patients aged 12-17
Subscribe for More Information
15:17 EDTGSKGlaxoSmithKline says FDA approves BREO ELLIPTA for adults with asthma
GlaxoSmithKline (GSK) and Theravance (THRX) announced that the FDA has approved BREO ELLIPTA for the once-daily treatment of asthma in patients aged 18 years and older. Breo Ellipta is not indicated for the relief of acute bronchospasm. Breo is a fixed-dose combination of the inhaled corticosteroid fluticasone furoate and the long-acting beta2-agonist vilanterol. Two strengths, 100/25mcg and 200/25mcg, have been approved in the US for use in asthma, administered once-daily using the Ellipta dry powder inhaler.
07:21 EDTGSKFDA PDUFA Date for Theravance BREO ELLIPTA is April 30, 2015
April 27, 2015
10:04 EDTGSKHigh option volume stocks
Subscribe for More Information
08:46 EDTGSKAgenus data positive, says JMP Securities
Subscribe for More Information
08:41 EDTGSKTelegraph discusses potential takeover of GSK by Pfizer
Subscribe for More Information
06:19 EDTGSKPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 24, 2015
07:11 EDTGSKAgenus: GSK's RTS,S vaccine showed statistically significant results in study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use